‘World-leading, ground breaking, shockingly fantastic, rock and roll science.’
That’s how Eliot Forster, chief executive of British biotech company Immunocore, talks about ImmTACS - the company’s novel class of biologic drugs.
ImmTACS - Immune mobilizing monoclonal TCRs Against Cancer – combine an affinity-enhanced T cell receptor (TCR)-based targeting system with an anti-CD3 (ScFv) effector function to activate a highly potent and specific T cell response to recognize and destroy cancer cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze